FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165681703> ?p ?o ?g. }

• W3165681703 endingPage "e1394" @default.
• W3165681703 startingPage "e1381" @default.
• W3165681703 abstract "Abstract Background Metastatic urothelial carcinoma (mUC) historically is treated with first-line platinum-based combination chemotherapy, preferably cisplatin plus gemcitabine whenever possible. In recent years, multiple classes of targeted therapy have demonstrated benefit, with some receiving approval in mUC. This review will summarize phase III efficacy and safety data for targeted agents, principally immune checkpoint inhibitors (ICIs), as either first-line or first-line switch-maintenance therapy for mUC and interpret these findings in the context of the current treatment landscape. Materials and Methods Published and presented phase III data on targeted therapy for the first-line or first-line switch-maintenance treatment of mUC were identified using the key search terms “targeted therapy” AND “urothelial carcinoma” AND “advanced” OR respective aliases according to the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results Of the six eligible phase III targeted therapy trials, two assessing ICIs met their primary endpoints in platinum-eligible patients. First-line ICI plus chemotherapy combinations have not improved overall survival (OS), although final OS results of the IMVigor 130 trial are pending. Switch-maintenance using an ICI in patients achieving at least stable disease following platinum-based chemotherapy statistically significantly improved OS (21.4 vs. 14.3 months, hazard ratio, 0.69; 95% confidence interval, 0.56–0.86; p = .001). Current sequencing options for mUC include first-line platinum-based chemotherapy with a switch to ICI either immediately or upon disease progression. Conclusion Recent targeted therapy trials have expanded ICI sequencing options for mUC. The treatment landscape is likely to evolve rapidly, with results from multiple phase III trials expected in the next 5 years. Implications for Practice Multiple classes of targeted agents are approved for use in metastatic urothelial carcinoma (mUC). Six phase III trials have recently provided insight on the benefit of these agents in the first-line setting. In platinum-eligible patients, immune checkpoint inhibitors (ICIs) combined with first-line platinum-based chemotherapy failed to demonstrate improved survival, although ICI monotherapy as switch-maintenance significantly improved overall survival in patients with mUC who had achieved at least stable disease following first-line platinum-based chemotherapy. In patients ineligible for any chemotherapy, pembrolizumab, atezolizumab, or pembrolizumab in combination with enfortumab vedotin may be options." @default.
• W3165681703 created "2021-06-07" @default.
• W3165681703 creator A5006433317 @default.
• W3165681703 creator A5006767981 @default.
• W3165681703 creator A5030597857 @default.
• W3165681703 creator A5037530844 @default.
• W3165681703 creator A5044972820 @default.
• W3165681703 creator A5061626918 @default.
• W3165681703 creator A5089306688 @default.
• W3165681703 date "2021-06-11" @default.
• W3165681703 modified "2023-10-16" @default.
• W3165681703 title "The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review" @default.
• W3165681703 cites W1594694899 @default.
• W3165681703 cites W1893740135 @default.
• W3165681703 cites W2030537668 @default.
• W3165681703 cites W2304807567 @default.
• W3165681703 cites W2541420108 @default.
• W3165681703 cites W2559804019 @default.
• W3165681703 cites W2588916311 @default.
• W3165681703 cites W2760661635 @default.
• W3165681703 cites W2803287610 @default.
• W3165681703 cites W2889646458 @default.
• W3165681703 cites W2890202689 @default.
• W3165681703 cites W2916220774 @default.
• W3165681703 cites W2919467556 @default.
• W3165681703 cites W2947751489 @default.
• W3165681703 cites W2951498948 @default.
• W3165681703 cites W2951548994 @default.
• W3165681703 cites W2954357619 @default.
• W3165681703 cites W2966500633 @default.
• W3165681703 cites W3007074770 @default.
• W3165681703 cites W3008618884 @default.
• W3165681703 cites W3012844237 @default.
• W3165681703 cites W3023288864 @default.
• W3165681703 cites W3024551702 @default.
• W3165681703 cites W3030041549 @default.
• W3165681703 cites W3031433077 @default.
• W3165681703 cites W3036701611 @default.
• W3165681703 cites W3087464965 @default.
• W3165681703 cites W3087466624 @default.
• W3165681703 cites W3087884839 @default.
• W3165681703 cites W3088055024 @default.
• W3165681703 cites W3088926900 @default.
• W3165681703 cites W3088957028 @default.
• W3165681703 cites W3127912627 @default.
• W3165681703 cites W3134461649 @default.
• W3165681703 cites W3135465744 @default.
• W3165681703 cites W3135615761 @default.
• W3165681703 cites W4242669880 @default.
• W3165681703 cites W4253567199 @default.
• W3165681703 doi "https://doi.org/10.1002/onco.13827" @default.
• W3165681703 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8342568" @default.
• W3165681703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34028134" @default.
• W3165681703 hasPublicationYear "2021" @default.
• W3165681703 type Work @default.
• W3165681703 sameAs 3165681703 @default.
• W3165681703 citedByCount "7" @default.
• W3165681703 countsByYear W31656817032022 @default.
• W3165681703 countsByYear W31656817032023 @default.
• W3165681703 crossrefType "journal-article" @default.
• W3165681703 hasAuthorship W3165681703A5006433317 @default.
• W3165681703 hasAuthorship W3165681703A5006767981 @default.
• W3165681703 hasAuthorship W3165681703A5030597857 @default.
• W3165681703 hasAuthorship W3165681703A5037530844 @default.
• W3165681703 hasAuthorship W3165681703A5044972820 @default.
• W3165681703 hasAuthorship W3165681703A5061626918 @default.
• W3165681703 hasAuthorship W3165681703A5089306688 @default.
• W3165681703 hasBestOaLocation W31656817031 @default.
• W3165681703 hasConcept C121608353 @default.
• W3165681703 hasConcept C126322002 @default.
• W3165681703 hasConcept C143998085 @default.
• W3165681703 hasConcept C151730666 @default.
• W3165681703 hasConcept C207103383 @default.
• W3165681703 hasConcept C2776694085 @default.
• W3165681703 hasConcept C2779343474 @default.
• W3165681703 hasConcept C2780258809 @default.
• W3165681703 hasConcept C2780352672 @default.
• W3165681703 hasConcept C2781230642 @default.
• W3165681703 hasConcept C2911057145 @default.
• W3165681703 hasConcept C3019882237 @default.
• W3165681703 hasConcept C44249647 @default.
• W3165681703 hasConcept C535046627 @default.
• W3165681703 hasConcept C71924100 @default.
• W3165681703 hasConcept C86803240 @default.
• W3165681703 hasConceptScore W3165681703C121608353 @default.
• W3165681703 hasConceptScore W3165681703C126322002 @default.
• W3165681703 hasConceptScore W3165681703C143998085 @default.
• W3165681703 hasConceptScore W3165681703C151730666 @default.
• W3165681703 hasConceptScore W3165681703C207103383 @default.
• W3165681703 hasConceptScore W3165681703C2776694085 @default.
• W3165681703 hasConceptScore W3165681703C2779343474 @default.
• W3165681703 hasConceptScore W3165681703C2780258809 @default.
• W3165681703 hasConceptScore W3165681703C2780352672 @default.
• W3165681703 hasConceptScore W3165681703C2781230642 @default.
• W3165681703 hasConceptScore W3165681703C2911057145 @default.
• W3165681703 hasConceptScore W3165681703C3019882237 @default.
• W3165681703 hasConceptScore W3165681703C44249647 @default.
• W3165681703 hasConceptScore W3165681703C535046627 @default.

• next